Related Experiment Video
Updated: Sep 5, 2025
The Intra-Aortic Balloon Pump
Published on: February 5, 2021
Inotrope and vasopressor use in cardiogenic shock: what, when and why?
Kira Hu1, Rebecca Mathew2,3
1Faculty of Medicine, University of Ottawa.
Insights
Management of cardiogenic shock (CS) relies on vasopressors and inotropes, but evidence for their efficacy is limited. Upcoming trials will investigate the necessity of inotropes in CS patients.
Area of Science:
- Cardiology
- Critical Care Medicine
- Pharmacology
Background:
- Cardiogenic shock (CS) management remains challenging with high mortality rates.
- Vasopressors and inotropes are standard supportive treatments for CS, despite limited evidence.
- Current guidelines recommend these agents, but their safety and efficacy in CS are not well-established.
Purpose of the Study:
- To review the current evidence on vasopressor and inotrope use in cardiogenic shock.
- To highlight recent trial findings and ongoing research in CS pharmacotherapy.
- To provide guidance on inotrope selection in the absence of definitive evidence.
Main Methods:
- Literature review of current studies and clinical trials in cardiogenic shock.
- Analysis of findings from OptimaCC and CAPITAL DOREMI trials.
- Discussion of upcoming placebo-controlled trials (CAPITAL DOREMI2, LevoHeartShock).
Main Results:
- Norepinephrine is supported as a first-line vasopressor in CS (OptimaCC trial).
- Milrinone showed no superiority over dobutamine in reducing morbidity/mortality in CS (CAPITAL DOREMI trial).
- No specific vasopressor or inotrope has demonstrated significant mortality benefit in CS patients.
Conclusions:
- Evidence for significant mortality benefit with specific vasopressors or inotropes in CS is lacking.
- Upcoming trials will provide crucial data on the necessity of inotropes in CS.
- Inotrope selection should be individualized, considering physician experience, availability, cost, and patient response.
Purpose Of Review:
Despite increasing interest in the management of cardiogenic shock (CS), mortality rates remain unacceptably high. The mainstay of supportive treatment includes vasopressors and inotropes. These medications are recommended in international guidelines and are widely used despite limited evidence supporting safety and efficacy in CS.
Recent Findings:
The OptimaCC trial further supports that norepinephrine should continue to be the first-line vasopressor of choice in CS. The CAPITAL DOREMI trial found that milrinone is not superior to dobutamine in reducing morbidity and mortality in CS. Two studies currently underway will offer the first evidence of the necessity of inotrope therapy in placebo-controlled trials: CAPITAL DOREMI2 will randomize CS patients to inotrope or placebo in the initial resuscitation of shock to evaluate the efficacy of inotrope therapy and LevoHeartShock will examine the efficacy of levosimendan against placebo in early CS requiring vasopressor therapy.
Summary:
Review of the current literature fails to show significant mortality benefit with any specific vasopressor or inotropic in CS patients. The upcoming DOREMI 2 and levosimendan versus placebo trials will further tackle the question of inotrope necessity in CS. At this time, inotrope selection should be guided by physician experience, availability, cost, and most importantly, individual patients' response to therapy.
More Related Videos
06:10Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
07:39Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
Published on: August 16, 2021
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
01:22Heart Failure Drugs: β-Blockers
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:23Antihypertensive Drugs: Vasodilators
01:30Heart Failure V: Medical Management